Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028675 · ClinicalTrials.gov registry record
pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 4
- Enrollment target
NCT03028675 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 4 participants.
The verdict
NCT03028675 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
Twenty subjects (10 patients and 10 age-matched control volunteers) will be recruited for this study. MRI scans will take place on a 3T MRI Scanner (Skyra or Prisma, Siemens Medical Solutions) located at The NYU Center for Biomedical Imaging. MRI scans will consist of a 1-hour brain scan for both patients and controls. In the first 6 months of the study, investigators will develop and test a uMT-based APT imaging for brain tissue pH measurement and use a hypercapnia paradigm to validate the tissue pH changes between breathing room air and 5% CO2 (by increasing tissue acidity) inhalation. With implementation of hypercapnia MRI, pH-weighted imaging will be validated for its robustness and reproducibility.
Interventions
- OTHER MRI Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2018-08-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03028675
The ClinicalTrials.gov registry entry for NCT03028675 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MRI Scan is the first listed.
NCT03028675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03028675 about?
NCT03028675 is a clinical study titled "pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress". Twenty subjects (10 patients and 10 age-matched control volunteers) will be recruited for this study. MRI scans will take place on a 3T MRI Scanner (Skyra or Prisma, Siemens Medical Solutions) located at The NYU Center for Biomedical Imaging. MRI scans will consist of a 1-hour brain scan for both pa...
What is the current status of trial NCT03028675?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2017-05-01. Estimated completion is 2018-08-10.
What interventions are being tested in trial NCT03028675?
The interventions under investigation include: MRI Scan (OTHER).
Who is sponsoring clinical trial NCT03028675?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.